Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2018 06:30 ET | Source: AC Immune SA

AC Immune and Lilly Announce License and Collaboration Agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial...
December 07, 2018 16:15 ET | Source: AC Immune SA

In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away

Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with...
November 15, 2018 04:00 ET | Source: AC Immune SA

AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease

Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's diseaseStart of first-in-human study of current lead is scheduled for Q1 2019Follow-up...
November 13, 2018 04:00 ET | Source: AC Immune SA

AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update

Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome Company record high, period end cash position of approximately CHF 200 million that is...
November 12, 2018 04:00 ET | Source: AC Immune SA

AC Immune to Present at the Jefferies 2018 London Healthcare Conference

Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
November 09, 2018 04:00 ET | Source: AC Immune SA

AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases

Increasing evidence points to Abeta oligomers as the toxic species in AD, and likely linked to Tau pathology and neuroinflammation. Immunotherapies and small molecule anti-Tau therapeutics hold...
November 01, 2018 06:00 ET | Source: AC Immune SA

AC Immune to Present at 2018 Society for Neurosciences Meeting

Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company...
November 01, 2018 05:00 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases

Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseasesMeeting scheduled for November 5, 2018, from 12:00pm...
October 29, 2018 06:00 ET | Source: AC Immune SA

AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620

Study confirms the good performance of tau PET-tracer 18F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11th...
October 29, 2018 05:00 ET | Source: AC Immune SA

AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy

Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's...